Applied Clinical Trials Online18h
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
Zacks Investment Research on MSN1h
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
AFP20h
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to JNJ Innovative ...